Biotech is dominating the (very) early 2026 deals market, whether that be startup fundings, IPOs, or mergers. Why it matters: This is a reversal of the usual order, in which biotech plays distant ...

Several Bay Area biotech companies announced big funding rounds totaling hundreds of millions of dollars just before the ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

For the third year in a row, Fierce Biotech’s Layoff Tracker is topping the tree as the story with the highest number of ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) is included in our list of the stocks under $1 that will explode. Oncolytics Biotech ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

A bevy of other companies also brought in money on Thursday, including Alveus Therapeutics, Diagonal Therapeutics, ...

Explore the Latest Research Peptides from Biotech Labz Supply Sebastopol, United States – January 4, 2026 / Biotech Labz Supply / Biotech Labz Supply has revealed an exciting enhancement of its ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

According to Gartner, 58% of finance functions employed AI in 2024—a 21-percentage-point jump from the prior year. PwC ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.